Annual Cash & Cash Equivalents
$88.46 M
-$22.43 M-20.23%
December 31, 2023
Summary
- As of February 7, 2025, ATOS annual cash & cash equivalents is $88.46 million, with the most recent change of -$22.43 million (-20.23%) on December 31, 2023.
- During the last 3 years, ATOS annual cash & cash equivalents has risen by +$48.91 million (+123.64%).
- ATOS annual cash & cash equivalents is now -35.14% below its all-time high of $136.38 million, reached on December 31, 2021.
Performance
ATOS Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$74.77 M
-$4.76 M-5.99%
September 30, 2024
Summary
- As of February 7, 2025, ATOS quarterly cash and cash equivalents is $74.77 million, with the most recent change of -$4.76 million (-5.99%) on September 30, 2024.
- Over the past year, ATOS quarterly cash and cash equivalents has dropped by -$19.27 million (-20.49%).
- ATOS quarterly cash and cash equivalents is now -47.51% below its all-time high of $142.43 million, reached on June 30, 2021.
Performance
ATOS Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ATOS Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -20.2% | -20.5% |
| 3 y3 years | +123.6% | -46.6% |
| 5 y5 years | +752.2% | -46.6% |
ATOS Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -35.1% | at low | -45.2% | at low |
| 5 y | 5-year | -35.1% | +603.1% | -47.5% | +901.9% |
| alltime | all time | -35.1% | >+9999.0% | -47.5% | >+9999.0% |
Atossa Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $74.77 M(-6.0%) |
| Jun 2024 | - | $79.53 M(-5.3%) |
| Mar 2024 | - | $83.96 M(-5.1%) |
| Dec 2023 | $88.46 M(-20.2%) | $88.46 M(-5.9%) |
| Sep 2023 | - | $94.03 M(-5.4%) |
| Jun 2023 | - | $99.39 M(-4.3%) |
| Mar 2023 | - | $103.87 M(-6.3%) |
| Dec 2022 | $110.89 M(-18.7%) | $110.89 M(-5.5%) |
| Sep 2022 | - | $117.37 M(-6.5%) |
| Jun 2022 | - | $125.54 M(-4.5%) |
| Mar 2022 | - | $131.49 M(-3.6%) |
| Dec 2021 | $136.38 M(+244.8%) | $136.38 M(-2.6%) |
| Sep 2021 | - | $140.04 M(-1.7%) |
| Jun 2021 | - | $142.43 M(+3.5%) |
| Mar 2021 | - | $137.57 M(+247.8%) |
| Dec 2020 | $39.55 M(+214.4%) | $39.55 M(+334.4%) |
| Sep 2020 | - | $9.11 M(+22.0%) |
| Jun 2020 | - | $7.46 M(-20.2%) |
| Mar 2020 | - | $9.35 M(-25.7%) |
| Dec 2019 | $12.58 M(+21.2%) | $12.58 M(-17.7%) |
| Sep 2019 | - | $15.29 M(-10.4%) |
| Jun 2019 | - | $17.06 M(-12.8%) |
| Mar 2019 | - | $19.57 M(+88.5%) |
| Dec 2018 | $10.38 M(+43.8%) | $10.38 M(-19.8%) |
| Sep 2018 | - | $12.94 M(-15.1%) |
| Jun 2018 | - | $15.24 M(+218.8%) |
| Mar 2018 | - | $4.78 M(-33.8%) |
| Dec 2017 | $7.22 M | $7.22 M(+164.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2017 | - | $2.73 M(-25.9%) |
| Jun 2017 | - | $3.69 M(+216.2%) |
| Mar 2017 | - | $1.17 M(-61.5%) |
| Dec 2016 | $3.03 M(-18.5%) | $3.03 M(-31.0%) |
| Sep 2016 | - | $4.39 M(+268.5%) |
| Jun 2016 | - | $1.19 M(-58.7%) |
| Mar 2016 | - | $2.88 M(-22.4%) |
| Dec 2015 | $3.72 M(-56.3%) | $3.72 M(-52.6%) |
| Sep 2015 | - | $7.84 M(-31.3%) |
| Jun 2015 | - | $11.40 M(+17.2%) |
| Mar 2015 | - | $9.73 M(+14.4%) |
| Dec 2014 | $8.50 M(+34.0%) | $8.50 M(-25.3%) |
| Sep 2014 | - | $11.37 M(-20.5%) |
| Jun 2014 | - | $14.30 M(-13.8%) |
| Mar 2014 | - | $16.59 M(+161.6%) |
| Dec 2013 | $6.34 M(+267.6%) | $6.34 M(-17.6%) |
| Sep 2013 | - | $7.69 M(+215.4%) |
| Jun 2013 | - | $2.44 M(+76.1%) |
| Mar 2013 | - | $1.39 M(-19.7%) |
| Dec 2012 | $1.73 M(-9.7%) | $1.73 M(+310.7%) |
| Sep 2012 | - | $420.10 K(+365.7%) |
| Jun 2012 | - | $90.20 K(-90.0%) |
| Mar 2012 | - | $899.50 K(-52.9%) |
| Dec 2011 | $1.91 M(>+9900.0%) | $1.91 M(-36.4%) |
| Sep 2011 | - | $3.01 M(>+9900.0%) |
| Dec 2010 | $10.30 K | $10.30 K(-65.1%) |
| Sep 2010 | - | $29.50 K(-8.1%) |
| Jun 2010 | - | $32.10 K |
FAQ
- What is Atossa Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Atossa Therapeutics?
- What is Atossa Therapeutics annual cash & cash equivalents year-on-year change?
- What is Atossa Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Atossa Therapeutics?
- What is Atossa Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Atossa Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of ATOS is $88.46 M
What is the all time high annual cash & cash equivalents for Atossa Therapeutics?
Atossa Therapeutics all-time high annual cash & cash equivalents is $136.38 M
What is Atossa Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, ATOS annual cash & cash equivalents has changed by -$22.43 M (-20.23%)
What is Atossa Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ATOS is $74.77 M
What is the all time high quarterly cash and cash equivalents for Atossa Therapeutics?
Atossa Therapeutics all-time high quarterly cash and cash equivalents is $142.43 M
What is Atossa Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, ATOS quarterly cash and cash equivalents has changed by -$19.27 M (-20.49%)